Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Healthcare
Create a narrative
Castle Biosciences Community
NasdaqGM:CSTL Community
1
Narratives
written by author
0
Comments
on narratives written by author
8
Fair Values set
on narratives written by author
Create a narrative
Castle Biosciences
Popular
Undervalued
Overvalued
Community Investing Ideas
Castle Biosciences
AN
AnalystConsensusTarget
Consensus Narrative from 9 Analysts
Anticipated Atopic Dermatitis Test Could Broaden Reach, Yet Medicare Coverage Concerns Persist
Key Takeaways Expanded product offerings, like the atopic dermatitis test, alongside increased market penetration could drive future revenue and growth. Strong clinician adoption, particularly for TissueCypher, coupled with a growing sales force, supports continued revenue expansion.
View narrative
US$35.89
FV
59.2% undervalued
intrinsic discount
-1.41%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
2 days ago
author updated this narrative
Your Valuation for
CSTL
CSTL
Castle Biosciences
Your Fair Value
US$
Current Price
US$14.65
21.0% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-72m
379m
2015
2018
2021
2024
2025
2027
2030
Revenue US$379.1m
Earnings US$28.7m
Advanced
Set Fair Value